LAGEVRI did not demonstrate statistically significant reduction in COVID risk following household exposure to another individual with COVID: Merck Ruchika Sharma23 Feb 2023 9:00 AM ISTRahway: Merck, known as MSD outside the United States and Canada, has announced that LAGEVRI (molnupiravir) did not demonstrate a statistically...
Pfizer, Merck rebuff China's push for deeper price cuts on COVID drugs: Bloomberg MD Bureau13 Jan 2023 3:14 PM ISTDelhi: Top US makers of Covid drugs appear to be pushing back on China's efforts to get them to cut their prices, underscoring the challenges the...
Molnupiravir may not lower hospitalization or mortality but hastens recovery in vaccinated COVID-19 patients: Lancet Dr. Kamal Kant Kohli24 Dec 2022 11:30 AM ISTResearchers have found in a new randomised controlled trial that Molnupiravir taken as an 800mg dose twice daily for five days may not lower...
Medical Bulletin 19/November/2022 Dr. Nandita Mohan19 Nov 2022 2:00 PM ISTHere are the top medical news for the day:Ultrasound-guided surgery is quicker, less painful and more effective for treating early form of breast...
Studies provide latest 'real world' evidence on effectiveness of covid-19 treatments Dr. Nandita Mohan19 Nov 2022 10:30 AM ISTThe debate around the effectiveness of COVID-19 treatments has been ongoing and often appears never-endingTwo studies published by The BMJ today...
Merck lifts full-year forecast as cancer immunotherapy Keytruda sales soar Ruchika Sharma29 Oct 2022 1:30 PM ISTMerck has been looking to pursue deals to protect itself from an eventual revenue loss as Keytruda patents begin to expire toward the end of the...
Merck agrees to allow Sinopharm to sell COVID drug molnupiravir in China Ruchika Sharma2 Oct 2022 3:30 PM ISTNew York: Drugmaker Merck & Co said on Wednesday that it agreed to allow China's Sinopharm to distribute and import its COVID-19 antiviral...
Early management of COVID-19 becoming an issue, says doctor Medical Dialogues Bureau23 March 2022 1:29 PM ISTWith vaccines and treatments available, ''we can make this much more manageable in the future if people are willing to take care of themselves," said...
WHO recommends Molnupiravir for high risk patients MD Bureau4 March 2022 12:09 PM ISTThe expert panel conditionally recommended the pill, molnupiravir, for patients with the non-severe disease who are at high risk of hospitalization.
Hetero COVID drug Molnupiravir shows positive results in Phase III trials Ruchika Sharma21 Feb 2022 4:37 PM ISTHyderabad: Hetero, a globally renowned vertically integrated pharmaceutical organization has recently announced the positive results of Phase III...
Merck expects 2022 sales up nearly 20 percent, mostly on molnupiravir Ruchika Sharma6 Feb 2022 9:00 AM ISTNew Delhi: Merck & Co said on Thursday it expects its 2022 sales to increase as much as 18 percent over last year, mostly on sales of its new...
Decoding safety, tolerability, and pharmacokinetics of Molnupiravir Dr. Kamal Kant Kohli4 Feb 2022 11:56 AM ISTMolnupiravir is a prodrug of active antiviral ribonucleoside analog b-D-N4-hydroxycytidine (NHC; EIDD-1931), with the potential to treat infections...
